BACKGROUND: Clinicopathological features and the outcomes of patients with fibrolamellar hepatocellular carcinoma (FLHCC) are not clearly defined. METHODS: Data were collected by retrospective chart review on 42 patients with FLHCC treated between 1990 and 2017 at Mayo Clinic. RESULTS: Of 42 patients (median age at diagnosis 22 years), 10 patients (23.8%) had stage I disease and 32 patients (76.2%) had stage II to IVB disease. All 10 patients with stage I disease and 21 of 32 patients with stage II-IVB disease underwent resection at presentation. In stage I patient group, 6 patients experienced recurrence with a median time to recurrence of 30.5 months and a 5-year overall survival (OS) of 86%. Patients with stage II to IVB disease who underwent resection (n=21) upfront had a median OS of 32.5 months and 5-year OS of 44%. In the upfront surgery group, 71% of patients experienced recurrence. The median OS of patients with unresectable disease (n=11) was 10 months. Four out of nine patients treated with sorafenib had stable disease and one patient with programmed cell death ligand-1 (PD-L1) expressing tumor had a near complete response after 2 months of therapy with nivolumab. CONCLUSIONS: In FLHCC, surgical resection was associated with prolonged OS; although most patients had a disease recurrence regardless of disease stage and resection margin status. The response to kinase inhibitor, sorafenib, was variable. In select cases, therapy with a checkpoint inhibitor may provide a viable treatment option.
BACKGROUND: Clinicopathological features and the outcomes of patients with fibrolamellar hepatocellular carcinoma (FLHCC) are not clearly defined. METHODS: Data were collected by retrospective chart review on 42 patients with FLHCC treated between 1990 and 2017 at Mayo Clinic. RESULTS: Of 42 patients (median age at diagnosis 22 years), 10 patients (23.8%) had stage I disease and 32 patients (76.2%) had stage II to IVB disease. All 10 patients with stage I disease and 21 of 32 patients with stage II-IVB disease underwent resection at presentation. In stage I patient group, 6 patients experienced recurrence with a median time to recurrence of 30.5 months and a 5-year overall survival (OS) of 86%. Patients with stage II to IVB disease who underwent resection (n=21) upfront had a median OS of 32.5 months and 5-year OS of 44%. In the upfront surgery group, 71% of patients experienced recurrence. The median OS of patients with unresectable disease (n=11) was 10 months. Four out of nine patients treated with sorafenib had stable disease and one patient with programmed cell death ligand-1 (PD-L1) expressing tumor had a near complete response after 2 months of therapy with nivolumab. CONCLUSIONS: In FLHCC, surgical resection was associated with prolonged OS; although most patients had a disease recurrence regardless of disease stage and resection margin status. The response to kinase inhibitor, sorafenib, was variable. In select cases, therapy with a checkpoint inhibitor may provide a viable treatment option.
Authors: Howard M Katzenstein; Mark D Krailo; Marcio H Malogolowkin; Jorge A Ortega; Wenchun Qu; Edwin C Douglass; James H Feusner; Marleta Reynolds; John J Quinn; Kurt Newman; Milton J Finegold; Joel E Haas; Martha G Sensel; Robert P Castleberry; Laura C Bowman Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: Sanjay Kakar; Lawrence J Burgart; Kenneth P Batts; Joaquin Garcia; Dhanpat Jain; Linda D Ferrell Journal: Mod Pathol Date: 2005-11 Impact factor: 7.842
Authors: G El-Gazzaz; W Wong; M K El-Hadary; B K Gunson; D F Mirza; A D Mayer; J A Buckels; P McMaster Journal: Transpl Int Date: 2000 Impact factor: 3.782
Authors: Gabriel G Malouf; Laurence Brugières; Marie-Cécile Le Deley; Sandrine Faivre; Monique Fabre; Valérie Paradis; Isabelle Aerts; Christophe Le Tourneau; Chantal Dreyer; Sophie Branchereau; Jacques Belghiti; Eric Raymond Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Stephen C Ward; Jiaoti Huang; Satish K Tickoo; Swan N Thung; Marc Ladanyi; David S Klimstra Journal: Mod Pathol Date: 2010-05-21 Impact factor: 7.842
Authors: Francesco Stipa; Sam S Yoon; Kui Hin Liau; Yuman Fong; William R Jarnagin; Michael D'Angelica; G Abou-Alfa; Leslie H Blumgart; Ronald P DeMatteo Journal: Cancer Date: 2006-03-15 Impact factor: 6.860
Authors: Hillary M Ross; Hubert D J Daniel; Perumal Vivekanandan; Rajesh Kannangai; Matthew M Yeh; Tsung-Teh Wu; Hala R Makhlouf; Michael Torbenson Journal: Mod Pathol Date: 2010-11-26 Impact factor: 7.842
Authors: Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias Journal: Oncologist Date: 2021-01-02
Authors: Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy Journal: Nat Rev Gastroenterol Hepatol Date: 2022-02-21 Impact factor: 73.082
Authors: Tomoki Sempokuya; Arnold Forlemu; Muaataz Azawi; Krixie Silangcruz; Nathalie Khoury; Jihyun Ma; Linda L Wong Journal: World J Clin Oncol Date: 2022-05-24
Authors: Anastasia Lemekhova; Daniel Hornuss; Georgios Polychronidis; Philipp Mayer; Christian Rupp; Thomas Longerich; Karl-Heinz Weiss; Markus Büchler; Arianeb Mehrabi; Katrin Hoffmann Journal: World J Surg Oncol Date: 2020-05-12 Impact factor: 2.754